Company intelligence / Profile preview

AURUM Group

United Kingdom

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Within AURUM Group, Aurum Biosciences is a clinical-stage biopharmaceutical spin-out (2015) developing its patented ABL-101 platform for acute stroke and other serious indications, with an Innovation Passport in the UK and ongoing clinical development; other AURUM Group activities include discovery and development of novel pharmaceuticals (including for addiction), hospital essential medicines, imaging technologies and healthcare services.[1][3][6]

Therapeutic areas: ImmunologyCardiovascularNeurologyPsychiatryOncology
Modalities: Small moleculeBiologicMonoclonal antibody
Industry: Biotech

Partnerships

NHS Greater Glasgow and ClydeUniversity of GlasgowInnoScot HealthVarious academic partners, government agencies, research centers and pharmaceutical companies worldwide

Beyond the preview

Go deeper on AURUM Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AURUM Group.

Explore the full profile